Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
- Registration Number
- NCT04968184
- Lead Sponsor
- KBP Biosciences
- Brief Summary
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate \[eGFR\] calculated using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula \[eGFR {EPI}\] ≥15 to ≤44 mL/min/1.73 m\^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and \<180 mm Hg and taking 2 or more antihypertensive medications.
- Detailed Description
Participants in this study will be recruited, screened, and enrolled at approximately 140 study sites globally.
The study will consist of the following periods:
1. Pretreatment Phase: This will include prescreening assessment and screening period of up to 4 weeks and 2-week Open-label placebo Run-In period.
2. A 24-week Double-blind Treatment Period (Randomization to Week 24) will include: An initial 12-week (Randomization to Week 12) and second 12-week (Week 12 to Week 24) treatment period and a second 12-week treatment period (Week 12 to Week 24), during both the periods study drug will be titrated.
3. A 24-week Open-label Treatment Period (Week 24 to Week 48) during which eligible participants will receive Open-label KBP-5074.
4. A 4-week Randomized Double-blind Withdrawal Period (Week 48 to Week 52) during which eligible participants will be randomized to continue their current KBP-5074 dose at the end of Open-label treatment or receive matching placebo for 4 weeks.
5. A 4-week post-treatment Follow-Up Period (Week 52 to Week 56).
During, 24-week Double-blind Treatment Period, 24-week Open-label Treatment Period, and at 4-week Randomized Double-blind Withdrawal Period, the background antihypertensive medications change may or may not be allowed.
At Double-blind Treatment Period, eligible participants will be randomly assigned in a 1:1 ratio to KBP-5074 0.25 mg or matching placebo once daily (QD).
At the Randomized Double-blind Withdrawal Period, participants who meet the randomized withdrawal criteria will be randomly assigned in a 1:1 ratio to continue their current KBP-5074 dose at the end of the Open-label Treatment Period or matching placebo QD.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 652
-
Body mass index (BMI) must be ≥19 to <45 kg/m^2 at the Screening Visit
-
Participant must have uncontrolled hypertension defined as meeting both of the following criteria:
- The participant has a resting seated trough cuff SBP ≥140 mm Hg at the Screening Visit (Visit 1), and at the start (Visit 2) and end (Visit 3) of the Run-In Period
- The participant is taking 2 or more antihypertensive medications that have been titrated upward as tolerated to hypertension target doses per local SoC and have been stable (i.e., without any dose adjustments) from 4 weeks before the Screening Visit (Visit 1) through the end of the Run-In Period (Visit 3)
-
The participant must have Stage 3b (eGFR [EPI] ≥30 and ≤44 mL/min/1.73 m^2) or Stage 4 (eGFR [EPI] ≥15 and <30 mL/min/1.73 m^2) CKD.
- Participant has a resting seated trough cuff SBP ≥180 mm Hg at the Screening Visit (Visit 1) or at the start (Visit 2) or end (Visit 3) of the Run-In Period
- Participant has a serum potassium level >4.8 mmol/L during the Screening or Run-In Periods
- Participant has had a serum potassium level >5.6 mmol/L within 2 weeks before the Screening Visit (Visit 1)
- Participant has been hospitalized for hyperkalemia within the 3 months before the Randomization Visit (Visit 3)
- Participant was not compliant with taking placebo during the Run-in Period or participant was not compliant with background antihypertensive medications during the Run-in Period as assessed at the Randomization Visit (Visit 3)
- Participant has taken an mineralocorticoid receptor antagonist (MRA), a potassium-sparing diuretic, or chronic potassium supplements during the 4 weeks before the Screening Visit (Visit 1)
- Participant has taken potassium binders for the treatment of hyperkalemia during the 3 months before the Screening Visit (Visit 1)
- Participant has taken a strong cytochrome P450 (CYP) CYP3A4 inducer or strong CYP3A4 inhibitor during the 7 days before the Randomization Visit (Visit 3)
- Participant has taken a prohibited traditional Chinese medication during the 28 days prior to Screening Visit (Visit 1).
- Participant was administered any other investigational product within 4 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit (Visit 1).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Open-label Placebo Run-In Period: All eligible participants will receive matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive matching placebo, from week 2 thru week 24 during the Double-blind treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56. KBP-5074 KBP-5074 Open-label Placebo Run-In period: All eligible participants will receive matching placebo, for approximately 2 weeks during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive KBP-5074, from week 2 thru week 24 during the Double-blind Treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56.
- Primary Outcome Measures
Name Time Method Change in seated trough cuff SBP from baseline to Week 12 From baseline to Week 12 Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, will be evaluated.
Change in seated trough cuff SBP from Week 48 to Week 52 Week 48 to Week 52 Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, will be evaluated.
- Secondary Outcome Measures
Name Time Method Change in seated trough cuff SBP from baseline to Week 24 From baseline to Week 24 Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, will be evaluated.
Percentage changes in UACR from baseline to Week 12, Week 24, and Week 48 From baseline to Week 12, Week 24, and Week 48 Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, will be evaluated.
Change in seated trough cuff DBP from Week 48 to Week 52 Week 48 to Week 52 Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, will be evaluated.
Percentage change in UACR from Week 48 to Week 52 Week 48 to Week 52 Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g, macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, will be evaluated.
Changes in seated trough cuff diastolic blood pressure (DBP) from baseline to Week 12 and Week 24 From baseline to Week 12 and Week 24 Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, will be evaluated.
Changes in seated trough cuff SBP and DBP from baseline to Week 48 From baseline to Week 48 Effect of KBP-5074 on SBP and DBP by assessing change in seated trough cuff SBP and DBP, will be evaluated.
Changes in urinary albumin: creatinine ratio (UACR) from baseline to Week 12 and Week 24 for participants with UACR ≥30 mg/g at baseline From baseline to Week 12 and Week 24 Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, will be evaluated.
Percentage changes in UACR from baseline to Week 12 and Week 24 for participants with UACR ≥30 mg/g at baseline From baseline to Week 12 and Week 24 Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, will be evaluated.
Changes in UACR from baseline to Week 12, Week 24, and Week 48 From baseline to Week 12, Week 24, and Week 48 Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, will be evaluated.
Change in UACR from Week 48 to Week 52 Week 48 to Week 52 Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g, macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, will be evaluated.
Number of participants with adverse events (AEs) and serious adverse events (SAEs) Screening (Week -6 to -2) until EOS (Week 56) or Unscheduled visit or end of treatment or early termination The safety and tolerability of KBP-5074,will be evaluated.
Trial Locations
- Locations (211)
Fides Clinical Research
🇺🇸Atlanta, Georgia, United States
Allied Biomedical Research Institute
🇺🇸Miami, Florida, United States
LCC Medical Research
🇺🇸Miami, Florida, United States
South Florida Research Phase I-Iv, Inc.
🇺🇸Miami, Florida, United States
Oceane 7 Medical&Research Center, Inc.
🇺🇸Miami, Florida, United States
DaVita Clinical Research (Nevada)
🇺🇸Las Vegas, Nevada, United States
National Heart Institute
🇺🇸Beverly Hills, California, United States
Renal Consultants Medical Group - Granada Hills
🇺🇸Northridge, California, United States
Kidney and Hypertension Center
🇺🇸Victorville, California, United States
Amicis Research Center (Valencia)
🇺🇸Granada Hills, California, United States
Massachusetts General Hospital (MGH) - Renal Associates Clinic
🇺🇸Boston, Massachusetts, United States
New Generation Of Medical Research
🇺🇸Naples, Florida, United States
Total Research Group
🇺🇸Miami, Florida, United States
Mattoo & Bhat Medical Associates, PC
🇺🇸Ridgewood, New York, United States
Central Georgia Kidney Specialists
🇺🇸Macon, Georgia, United States
InterMed Consultants
🇺🇸Edina, Minnesota, United States
NYC Health + Hospitals / Queens - Diabetes Center of Excellence
🇺🇸Jamaica, New York, United States
North Carolina Nephrology P.A.
🇺🇸Raleigh, North Carolina, United States
Knoxville Kidney Center, PLLC
🇺🇸Knoxville, Tennessee, United States
University Hospital Centre Zagreb
🇭🇷Zagreb, Grad Zagreb, Croatia
Nemocnice Trebic, p.o.
🇨🇿Trebic, Třebíč, Czechia
Rabin Medical Center
🇮🇱Petah Tikwa, HaMerkaz, Israel
Diabeteszentrum DO
🇩🇪Dortmund, Nordrhein-Westfalen, Germany
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic of
Nefrologie s.r.o.
🇨🇿Praha, Praha 4, Czechia
Alaron s.r.o.
🇨🇿Praha 6, Czechia
University Hospital Center Split
🇭🇷Split, Croatia
DaVita Clinical Research Germany GmbH
🇩🇪Düsseldorf, Nordrhein-Westfalen, Germany
Opca bolnica Vinkovci
🇭🇷Vinkovci, Osjecko-baranjska Županija, Croatia
IKEM
🇨🇿Praha 4, Czechia
Emergency Cardiology Center named by acad. G. Chapidze
🇬🇪Tbilisi, Georgia
J.S.C."K.Eristavi National Center of Experimental and Clinical Surgery"
🇬🇪Tbilisi, Georgia
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Nazareth Hospital EMMS
🇮🇱Nazareth, HaZafon, Israel
Charité - Universitätsmedizin Berlin
🇩🇪Berlin, Germany
Hospital Universitario Virgen de las Nieves
🇪🇸Granada, Spain
Charlotte Maxeke Johannesburg Hospital
🇿🇦Soweto, Gauteng, South Africa
FUNDACION PUIGVERT - Nephrology Department
🇪🇸Barcelona, Spain
Gangnam Severance Hospital, Yonsei University Health System - Internal Medicine
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic of
Clinical Hospital Centre Zemun
🇷🇸Zemun, Belgrade, Serbia
Hospital Universitario Fundación Jiménez Díaz
🇪🇸Madrid, Spain
Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Nephrology
🇨🇳Taoyuan, Taiwan
Hospital Universitario Y Politécnico La Fe
🇪🇸Valencia, Spain
Clinical Advancement Center, PLLC
🇺🇸San Antonio, Texas, United States
Urology San Antonio - North Central
🇺🇸San Antonio, Texas, United States
DaVita Clinical Research
🇺🇸San Antonio, Texas, United States
The First Affiliated Hospital of Xiamen University
🇨🇳Xiamen, Fujian, China
The People's Hospital of Guangxi Zhuang Autonomous Region- Nephrology
🇨🇳Nanning, Guangxi, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, Guangdong, China
The Second Hospital of Hebei Medical University
🇨🇳Shijiazhuang, Hebei, China
The Second Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
Shanghai General Hospital
🇨🇳Shanghai, Shanghai, China
Office of Gulam Hoosain Vally
🇿🇦Durban, Kwazulu-Natal, South Africa
Coromed-Smo Kft.
🇭🇺Pécs, Baranya, Hungary
Mhat Dr.Tota Venkova
🇧🇬Gabrovo, Bulgaria
Aleksandre Aladashvili Clinic LLC
🇬🇪Tbilisi, Georgia
Tung Wah Hospital
🇭🇰Hong Kong, Hong Kong
Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
🇵🇱Lublin, Poland
MSB General hospital - Clinical Research Center
🇷🇸Belgrade, Serbia
Bokhua Memorial Cardiovascular Centre
🇬🇪Tbilisi, Georgia
Sonocor Egészségügyi Szolgáltató Kft.
🇭🇺Szeged, Csongrád, Hungary
BKS Research
🇭🇺Hatvan, Heves, Hungary
DRC Gyógyszervizsgáló Központ Kft.
🇭🇺Balatonfüred, Veszprém City, Hungary
Hospital Seri Manjung
🇲🇾Seri Manjung, Perak, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
Clinical Center Kragujevac
🇷🇸Kragujevac, Serbia
Nephrologisches Zentrum Villingen-Schwenningen
🇩🇪Villingen-Schwenningen, Baden-Württemberg, Germany
JSC German Clinic
🇬🇪Tbilisi, Georgia
Ltd Marnecor
🇬🇪Marneuli, Kvemo Kartli, Georgia
JSC "Evex Hospitals'
🇬🇪Batumi, Georgia
Ministry of Defence of Georgia LEPL Giorgi Abramishvili Military Hospital
🇬🇪Gori, Shida Kartli, Georgia
LTD "High technology hospital MEDCENTER"
🇬🇪Batumi, Ajaria, Georgia
LTD Israel-Georgian Medical Research Clinic Helsicore
🇬🇪Tbilisi, Georgia
"Pineo Medical Ecosystem"LTD
🇬🇪Tbilisi, Georgia
Queen Mary Hospital - Medicine
🇭🇰Hong Kong, Hong Kong
Synexus Polska Sp. z o.o.
🇵🇱Warszawa, Poland
Synexus Polska Sp. z. o.o.
🇵🇱Lodz, Poland
National Taiwan University Hospital - Nephrology
🇨🇳Taipei, Taipei Special Muncipality, Taiwan
Hospital Raja Perempuan Zainab II
🇲🇾Kota Bharu, Kelantan, Malaysia
TaNa Med Kft
🇭🇺Mosonmagyaróvár, Gyor-Moson-Sopron, Hungary
Somogy Megyei Kaposi Mór Oktató Kórház
🇭🇺Kaposvár, Hungary
Dace Teterovska - Doctor's Practice
🇱🇻Ogre, Ogres Novads, Latvia
Saules seimos medicinos centras
🇱🇹Kaunas, Kauno Apskritis, Lithuania
NZOZ Euromedica Sp. z o.o.
🇵🇱Grudziądz, Kujawsko-pomorskie, Poland
SP ZOZ Centralny Szpital Kliniczny UM w Lodzi
🇵🇱Lodz, Poland
Clinical Centre Nis
🇷🇸Niš, Nišavski Okrug, Serbia
Clinical Center Vojvodina
🇷🇸Novi Sad, Vojvodina, Serbia
Semmelweis Egyetem
🇭🇺Budapest, Hungary
IPR Hungary Kft.
🇭🇺Miskolc, Borsod-Abaúj-Zemplén, Hungary
Tiervlei Trial Centre
🇿🇦Bellville, Cape Town, Western Cape, South Africa
Kistarcsai Flor Ferenc Korhaz
🇭🇺Kistarcsa Hungary, Pest, Hungary
Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer
🇵🇱Lodz, Lódzkie, Poland
Zvezdara University Medical Center
🇷🇸Belgrade, Serbia
Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet
🇭🇺Budapest, Hungary
China Medical University Hospital - Nephrology - Taichung
🇨🇳Taichung, Taiwan
Universitätsklinikum Mainz
🇩🇪Mainz, Rheinland-Pfalz, Germany
Universitätsklinikum Jena
🇩🇪Jena, Germany
Hospital de La Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Genesis Clinical Research
🇺🇸Tampa, Florida, United States
Santos Research Center CORP
🇺🇸Tampa, Florida, United States
Hospital público da Mariña
🇪🇸Burela, Lugo, Spain
G & L Research, LLC
🇺🇸Foley, Alabama, United States
Aventiv Research, Inc
🇺🇸Mesa, Arizona, United States
Apogee Clinical Research, LLC
🇺🇸Huntsville, Alabama, United States
United Clinical Research and Innovations
🇺🇸S. Gate, California, United States
Amicis Research Center
🇺🇸Lancaster, California, United States
Desert Cities Dialysis - Amethyst
🇺🇸Victorville, California, United States
Davita Clinical Research-Hartford
🇺🇸Bloomfield, Connecticut, United States
Synergy Healthcare
🇺🇸Bradenton, Florida, United States
Columbus Associates LLC
🇺🇸Columbus, Georgia, United States
Clinical Investigation Specialists, Inc.
🇺🇸Gurney, Illinois, United States
St. Louis Heart and Vascular, P.C. (SLHV) - Christian Hospital Office
🇺🇸Saint Louis, Missouri, United States
Physicians East, PA
🇺🇸Greenville, North Carolina, United States
Eastern Nephrology Associates - New Bern
🇺🇸New Bern, North Carolina, United States
Providence Health Partners-Center for Clinical Research
🇺🇸Dayton, Ohio, United States
Columbia Nephrology Associates, PA
🇺🇸Columbia, South Carolina, United States
Davita Clinical Research El Paso
🇺🇸El Paso, Texas, United States
DaVita Clinical Research Houston
🇺🇸Houston, Texas, United States
Pioneer Research Solutions, Inc.
🇺🇸Houston, Texas, United States
Kidney Specialists of North Houston, PLLC
🇺🇸The Woodlands, Texas, United States
Milwaukee Nephrologists, SC (Rich)
🇺🇸Wauwatosa, Wisconsin, United States
Renal Research
🇦🇺Gosford, New South Wales, Australia
Austin Hospital
🇦🇺Heidelberg, Victoria, Australia
Clinical Center University of Sarajevo
🇧🇦Sarajevo, Kanton Sarajevo, Bosnia and Herzegovina
Univerzitetski klinicki centar Republike Srpske - Internal Medicine, Nephrology
🇧🇦Banja Luka, Republika Srpska, Bosnia and Herzegovina
The University Hospital Foca
🇧🇦Foca, Republika Srpska, Bosnia and Herzegovina
General Hospital Gradiska
🇧🇦Gradiska, Republika Srpska, Bosnia and Herzegovina
General Hospital Tesanj
🇧🇦Tešanj, Zeničko-dobojski Kanton, Bosnia and Herzegovina
5 th MHAT
🇧🇬Sofia, Sofia-Grad, Bulgaria
General hospital Trebinje - Gastroenterology
🇧🇦Trebinje, Republika Srpska, Bosnia and Herzegovina
Medical Center Excelsior
🇧🇬Sofia, Sofia-Grad, Bulgaria
UMHAT St. Ekaterina
🇧🇬Sofia, Sofia-Grad, Bulgaria
Medical Center Hera EOOD
🇧🇬Sofia, Bulgaria
Comac Medical Ltd
🇧🇬Sofia, Sofia-Grad, Bulgaria
UMHAT Kaspela
🇧🇬Plovdiv, Bulgaria
Medical Center "Teodora"
🇧🇬Ruse, Bulgaria
DCC 22 - Sofia
🇧🇬Sofia, Bulgaria
University Hospital of Active Treatment Prof. Stoyan Kirkovich
🇧🇬Stara Zagora, Bulgaria
Dr. Stephen S. Chow Medicine Professional Corporation
🇨🇦Toronto, Ontario, Canada
Medical Center ''Synexus Sofia'' EOOD
🇧🇬Sofia, Bulgaria
MHAT"Sv.Anna-Varna"AD
🇧🇬Varna, Bulgaria
Clinical Research Solutions Incorporated
🇨🇦Waterloo, Ontario, Canada
Beijing Chao-Yang Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
Beijing An Zhen Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
China-Japan Friendship Hospital
🇨🇳Beijing, Beijing, China
Beijing Hospital
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital of Fujian Medical University
🇨🇳Fuzhou, Fujian, China
The Third Affiliated Hospital, Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Zhongshan Hospital Xiamen University
🇨🇳Xiamen, Fujian, China
Guangzhou First People's Hospital - Nephrology
🇨🇳Guangzhou, Guangdong, China
The Affliated Hospital of Guizhou Medical University
🇨🇳Guiyang, Guizhou, China
The First Affiliated Hospital of Zhengzhou University (East Compus)
🇨🇳Zhengzhou, Henan, China
The Central Hospital of Wuhan
🇨🇳Wuhan, Hubei, China
The Third Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
Southeastern Clinical Research Institute, LLC
🇺🇸Augusta, Georgia, United States
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
🇨🇳Baotou, Nei Mongol (mn), China
Jiangsu Province Hospital/ The First Affiliated Hospital with Nanjing Medical University
🇨🇳Nanjing, Jiangsu, China
Wuxi People's Hospital
🇨🇳Wuxi, Jiangsu, China
Sarkis Clinical
🇺🇸Ocala, Florida, United States
Inpatient Research Clinic, LLC
🇺🇸Miami Lakes, Florida, United States
Solano Kidney Care
🇺🇸Vacaville, California, United States
General Hospital of Ningxia Medical University
🇨🇳Yinchuan, Ningxia, China
Homestead Associates in Research, Inc
🇺🇸Miami, Florida, United States
San Marcus Research Clinic, Inc.
🇺🇸Miami Lakes, Florida, United States
Mountain Kidney & Hypertension Associates (MKHA), P.A - Asheville
🇺🇸Asheville, North Carolina, United States
Clinical Investigation Specialists
🇺🇸Kenosha, Wisconsin, United States
Davita Norfolk Square
🇺🇸Norfolk, Virginia, United States
The First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Shandong Provincial Hospital
🇨🇳Jinan, Shandong, China
Sichuan Academy of Medical Sciences
🇨🇳Chengdu, Sichuan, China
Zhejiang Hospital
🇨🇳Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
Yantai Yuhuangding Hospital(Base Cpmpus)
🇨🇳Yantai, Shandong, China
Zhejiang Provincial People's Hospital
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
Jinhua Central Hospital
🇨🇳Jinhua, Zhejiang, China
The Southwest Hospital of AMU
🇨🇳Chongqing, China
Shanghai Sixth People's Hospital
🇨🇳Shanghai, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, China
National Center of Urology Named after Laur Managadze
🇬🇪Tbilisi, Georgia
Charité- Universitätsmedizin Berlin
🇩🇪Berlin, Germany
Chungnam National University Hospital - Nephrology
🇰🇷Daejeon, Daejeon Gwang'yeogsi [Taejon-Kwangyokshi], Korea, Republic of
Seoul National University Hospital - Nephrology
🇰🇷Jongno-gu, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic of
P.Stradina Clinical University Hospital
🇱🇻Riga, Latvia
Samsung Medical Center - Nephrology
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic of
Hospital Kuala Lumpur
🇲🇾Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
WroMedica I. Bielicka, A. Strzalkowska s.c.
🇵🇱Wrocław, Poland
Military Medical Academy
🇷🇸Belgrade, Serbia
Iatros International
🇿🇦Bloemfontein, Free State, South Africa
Hospital Ribera Polusa
🇪🇸Burela, Lugo, Spain
Consorcio Hospital General Universitario de Valencia
🇪🇸Valencia, Valenciana, Comunidad, Spain
Dr J.M. Engelbrecht Trial Site
🇿🇦Somerset West, Western Cape, South Africa
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital Quironsalud Barcelona
🇪🇸Barcelona, Spain
Taichung Veterans General Hospital - Nephrology
🇨🇳Taichung, Taichung Municipality, Taiwan
Taipei Medical University - Shuang Ho Hospital - Nephrology
🇨🇳Taipei, Taiwan
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Healor Primary Care /CCT Research
🇺🇸Las Vegas, Nevada, United States
Kidney Consultants of El Paso, P.A.
🇺🇸El Paso, Texas, United States
Healthcare Research Network
🇺🇸Hazelwood, Missouri, United States
National Health Insurance Service Ilsan Hospital - Nephrology
🇰🇷Goyang-si, Gyeonggido [Kyonggi-do], Korea, Republic of
Eastern Nephrology Associates - Jacksonville
🇺🇸Jacksonville, North Carolina, United States
Omega Research Orlando, LLC
🇺🇸Orlando, Florida, United States
Brookview Hills Research Associates, LLC
🇺🇸Winston-Salem, North Carolina, United States
Dominion Medical Associates, Inc.
🇺🇸Richmond, Virginia, United States
Clinical Research Consultants
🇺🇸Kansas City, Missouri, United States
Gamma Clinical Research Institute
🇺🇸Austin, Texas, United States
Albert Einstein's College of Medicine
🇺🇸Bronx, New York, United States
Kidney Medical Associates, PLLC
🇺🇸Bronx, New York, United States
Hospital Raja Permaisuri Bainun
🇲🇾Ipoh, Perak, Malaysia
Peking University First Hospital
🇨🇳Beijing, Beijing, China